Abstract. In this study, a peptide-based dual-targeting magnetic resonance imaging (MRI) contrast agent (S8) was designed and synthesized. Arg-Gly-Asp (RGD) and Asn-Gly-Arg (NGR) were combined in the targeting vector so as to allow binding, on the surface of tumor cells, to integrin α v β 3 and aminopeptidase N (CD 13 ), respectively. The longitudinal relaxivity (r 1 ) value of S8 was 8.297 mM -1 sec -1 at a magnetic field of 11.7 T, which is approximately double the r 1 value (4.25 mM -1 sec -1 ) of Magnevist, a commercially available contrast agent. MDA-MB-231 human breast cancer cells (which overexpress α v β 3 ) and human prostate cancer cells PC-3 (which overexpress CD 13 ) were used to investigate the tumor-targeting behavior of S8. The results from the present study indicate that the designed contrast agent, S8, targets both MDA-MB-231 and PC-3 cells.